Skip First Level Navigation | Skip All Navigation
|Home | Contact Us | Frequently Asked Questions||
Site Map |
Home > News > Press Releases > AstraZeneca to Pay $520 Million to Settle Claims of Off-Label Drug Marketing
AstraZeneca to Pay $520 Million to Settle Claims of Off-Label Drug Marketing
April 27, 2010
Contact: Kate Simmons (207) 626-8577
Augusta- Attorney General Janet T. Mills announced today that Maine has joined with other states and the federal government to reach an agreement in principle with AstraZeneca Pharmaceuticals LP, to settle allegations that it engaged in an off-label marketing campaign that improperly promoted the antipsychotic drug, Seroquel. AstraZeneca will pay the states and the federal government a total of $520 million in damages and penalties to compensate Medicaid and various federal healthcare programs for harm suffered as a result of this conduct. Maine will receive over $1.2 million in restitution and additional recoveries.
Seroquel is one of a newer generation of antipsychotic medications (called atypical antipsychotics) used to treat certain psychological disorders. From January 1, 2001 through December 31, 2006, AstraZeneca promoted the sale and use of Seroquel for certain uses that the Food and Drug Administration had not approved. The settlement resolves a government investigation into promotional activities undertaken by AstraZeneca that were directed not only to psychiatrists but also to primary care physicians and other health care professionals for unapproved uses in the treatment of medical conditions such as aggression, Alzheimer’s disease, anger management, anxiety, attention deficit hyperactivity disorder, dementia and sleeplessness.
In implementing its marketing campaign, AstraZeneca was also alleged to have made illegal payments to physicians, paying their way to travel to resort locations to “advise” AstraZeneca about marketing messages for unapproved uses, to serve as authors of articles written by AstraZeneca and its agents, and to conduct studies for unapproved uses of Seroquel. The settlement resolves claims that these promotional activities caused physicians to prescribe Seroquel for children, adolescents and dementia patients in long term care facilities. These uses were not medically accepted indications for which state Medicaid programs would approve reimbursement for Seroquel.
“AstraZeneca improperly marketed Seroquel to physicians for uses that not were not approved by the FDA at an extreme cost to the state of Maine,” stated Attorney General Mills. “This agreement requires AstraZeneca to make restitution to account for the costs of such illegal marketing activity.”
As part of the settlement, AstraZeneca will enter into a Corporate Integrity Agreement with the United States Department of Health and Human Services, Office of the Inspector General, which will closely monitor the company’s future marketing and sales practices.
This settlement is based on qui tam cases that were filed in the United States District Court for the Eastern District of Pennsylvania by relators – private parties who filed actions under state and federal false claims statutes.
A National Association of Medicaid Fraud Control Units team participated in the investigation and conducted the settlement negotiations with AstraZeneca on behalf of the settling states. Attorney General Mills thanks Assistant Attorney General Michael Miller for her excellent work on this case.
|Copyright © 2007 All rights reserved.|